Six analysts currently cover Recursion Pharmaceuticals and have assigned a consensus rating of Hold. Coverage includes one Sell rating, three Hold ratings and two Buy ratings. Over the past year, these brokers have established an average twelve-month price target of 9.40 for the stock.

On December 17, JPMorgan Chase & Co. upgraded Recursion from Neutral to Overweight and raised its target to 11.00. On the same day, Morgan Stanley and UBS Group each set targets of 11.00, while Weiss Ratings maintained a Sell (D-) assessment on October 8. These updates reflect growing confidence among major firms in the company’s platform and clinical prospects.

In early January, Director Blake Borgeson sold 220,000 shares for a total of approximately 959,200, reducing his holdings by 3.2% to 6,649,863 shares. In late December, CFO Ben R. Taylor sold 21,383 shares totaling about 89,380. Collectively, insiders disposed of 585,786 shares valued at roughly 2.56 million over the past ninety days, representing 8.43% of total insider ownership.

UBS Asset Management Americas nearly tripled its stake by adding 4,149,346 shares in Q1 to hold 6,408,524 shares valued at 33.9 million. Norges Bank initiated a position worth 16.0 million in Q2, while Bank Pictet & Cie Europe AG established a new stake of 7.95 million in Q3. Stratos Wealth Partners increased its holding by 724.3% to 98,704 shares (499,000) in Q2, and Ethic Inc. entered with a 107,000 position. Hedge funds and institutions now own 89.06% of the company’s shares.

In its November quarter, Recursion reported adjusted net loss per share of 0.36, outperforming the consensus estimate by 0.02. Revenue totaled 5.18 million, falling short of the 19.36 million forecast and marking an 80.1% decline from the prior-year period. The company’s return on equity was negative 72.7% and net margin negative 1,637.8%. Equities analysts project a full-year loss per share of 1.57.